JP2005500379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500379A5 JP2005500379A5 JP2003521195A JP2003521195A JP2005500379A5 JP 2005500379 A5 JP2005500379 A5 JP 2005500379A5 JP 2003521195 A JP2003521195 A JP 2003521195A JP 2003521195 A JP2003521195 A JP 2003521195A JP 2005500379 A5 JP2005500379 A5 JP 2005500379A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- alkyl
- hydrogen
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- -1 heteroaryl radical Chemical class 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000003254 radicals Chemical class 0.000 claims 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000004423 acyloxy group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 6
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 230000037356 lipid metabolism Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000002243 precursor Substances 0.000 claims 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 210000001789 adipocyte Anatomy 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 230000004069 differentiation Effects 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- CLMAMNHVEQHTLG-UHFFFAOYSA-N CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(C=NO)=CC=C1OC(F)(F)F Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(C=NO)=CC=C1OC(F)(F)F CLMAMNHVEQHTLG-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical class [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 2
- 150000005840 aryl radicals Chemical class 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- CTWSMVXLNINGLR-UHFFFAOYSA-N CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(C=NO)=C(O)C=C1O Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(C=NO)=C(O)C=C1O CTWSMVXLNINGLR-UHFFFAOYSA-N 0.000 claims 1
- NUSYGBVIJLLJRF-UHFFFAOYSA-N CN(C)C1=CC=C(C=NO)C=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C Chemical compound CN(C)C1=CC=C(C=NO)C=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C NUSYGBVIJLLJRF-UHFFFAOYSA-N 0.000 claims 1
- BTLRMFQGIGHLOC-UHFFFAOYSA-N COC1=CC(O)=C(C=NO)C=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C Chemical compound COC1=CC(O)=C(C=NO)C=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C BTLRMFQGIGHLOC-UHFFFAOYSA-N 0.000 claims 1
- QAYMQKFBFDENIE-UHFFFAOYSA-N COC1=CC=C(C=NO)C=C1C(C(=C1)C)=CC2=C1N(C(C)C)CCN2C(C)C Chemical compound COC1=CC=C(C=NO)C=C1C(C(=C1)C)=CC2=C1N(C(C)C)CCN2C(C)C QAYMQKFBFDENIE-UHFFFAOYSA-N 0.000 claims 1
- DVZXYDBMHWPJDO-UHFFFAOYSA-N COC1=CC=C(C=NO)N=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C Chemical compound COC1=CC=C(C=NO)N=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C DVZXYDBMHWPJDO-UHFFFAOYSA-N 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 150000001543 aryl boronic acids Chemical class 0.000 claims 1
- 150000001502 aryl halides Chemical class 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000012954 diazonium Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- IEQFVJLASNEFLM-UHFFFAOYSA-N n-[[2,4-dimethoxy-5-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)phenyl]methylidene]hydroxylamine Chemical compound C1=C(C=NO)C(OC)=CC(OC)=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C IEQFVJLASNEFLM-UHFFFAOYSA-N 0.000 claims 1
- BUBSYAXYZDYSJQ-UHFFFAOYSA-N n-[[2-fluoro-4-methoxy-3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)phenyl]methylidene]hydroxylamine Chemical compound COC1=CC=C(C=NO)C(F)=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C BUBSYAXYZDYSJQ-UHFFFAOYSA-N 0.000 claims 1
- NDGOOISJAICEDN-UHFFFAOYSA-N n-[[4-methoxy-3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)phenyl]methylidene]hydroxylamine Chemical compound COC1=CC=C(C=NO)C=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C NDGOOISJAICEDN-UHFFFAOYSA-N 0.000 claims 1
- RYQCAAFGLNQKDR-UHFFFAOYSA-N n-[[6-methoxy-5-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)pyridin-3-yl]methylidene]hydroxylamine Chemical compound COC1=NC=C(C=NO)C=C1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C RYQCAAFGLNQKDR-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31319901P | 2001-08-17 | 2001-08-17 | |
| PCT/US2002/026476 WO2003016267A1 (en) | 2001-08-17 | 2002-08-19 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500379A JP2005500379A (ja) | 2005-01-06 |
| JP2005500379A5 true JP2005500379A5 (https=) | 2005-11-17 |
Family
ID=23214760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003521195A Pending JP2005500379A (ja) | 2001-08-17 | 2002-08-19 | 異脂肪血症および高コレステロール血症を治療するオキシム誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20030083357A1 (https=) |
| EP (1) | EP1421061A4 (https=) |
| JP (1) | JP2005500379A (https=) |
| WO (1) | WO2003016267A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508391A (ja) | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用 |
| AU2002252227A1 (en) * | 2001-03-07 | 2002-09-24 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| JP2004523571A (ja) * | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒ活性化分子 |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US20050038098A1 (en) * | 2003-04-18 | 2005-02-17 | Catherine Tachdjian | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| JP4780372B2 (ja) * | 2005-03-02 | 2011-09-28 | 独立行政法人産業技術総合研究所 | キノキサリンジオン誘導体及びその製造方法並びにその用途 |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| DK3204357T3 (da) * | 2014-10-10 | 2022-04-04 | High Force Res Limited | Fluorescerende, syntetiske retinoider |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051842A (en) * | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) * | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| US4383529A (en) * | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4971996A (en) * | 1987-03-11 | 1990-11-20 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors |
| US5223522A (en) * | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5330998A (en) * | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| EP0595868B1 (en) * | 1991-07-22 | 1998-11-25 | Pfizer Inc. | Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene |
| US5780676A (en) * | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| NZ248573A (en) * | 1992-09-10 | 1996-02-27 | Lilly Co Eli | 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions |
| US5691376A (en) * | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
| EP0745063B1 (en) * | 1994-02-17 | 1999-03-24 | American Home Products Corporation | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
| TR199900684T2 (xx) * | 1996-07-08 | 1999-07-21 | Galderma Research & Development, S.N.C. | Apoptoz uyar�c� adamantil t�revleri ve bunlar�n kansere kar�� maddeler olarak kullan�m�. |
| US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| US6462032B1 (en) * | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| JP2003508391A (ja) * | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用 |
| FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| AU2002252227A1 (en) * | 2001-03-07 | 2002-09-24 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| JP2004523571A (ja) * | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒ活性化分子 |
| JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環 |
| AR037714A1 (es) * | 2001-12-06 | 2004-12-01 | Maxia Pharmaceuticals Inc | Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US20050014767A1 (en) * | 2003-01-29 | 2005-01-20 | Magnus Pfahl | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
| US20050038098A1 (en) * | 2003-04-18 | 2005-02-17 | Catherine Tachdjian | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
-
2002
- 2002-08-19 WO PCT/US2002/026476 patent/WO2003016267A1/en not_active Ceased
- 2002-08-19 US US10/224,288 patent/US20030083357A1/en not_active Abandoned
- 2002-08-19 EP EP02794929A patent/EP1421061A4/en not_active Withdrawn
- 2002-08-19 JP JP2003521195A patent/JP2005500379A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI376370B (en) | Compounds for inflammation and immune-related uses | |
| CN1133627C (zh) | N-苄基二氧代噻唑烷基苯甲酰胺衍生物的制造中间体及其制造方法 | |
| JP2007523155A5 (https=) | ||
| JP2005500379A5 (https=) | ||
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| JP2005539088A5 (https=) | ||
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| Mourão et al. | Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones | |
| TNSN07361A1 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| CA2613303A1 (en) | An oxime derivative for use as a glucokinase activator | |
| JP2007535551A5 (https=) | ||
| JPWO1994014769A1 (ja) | Ｎ−置換インドール誘導体 | |
| CA2503117A1 (en) | Substituted 4-alkoxyoxazol derivatives as ppar agonists | |
| CA2412941A1 (en) | Piperidine compounds for use as ccr-3 inhibitors | |
| JP2005511516A5 (https=) | ||
| JP2005526696A5 (https=) | ||
| JP2001525394A5 (https=) | ||
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| KR100608416B1 (ko) | 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체 | |
| JP2005530705A5 (https=) | ||
| CA2626402A1 (en) | Potassium channel inhibitors | |
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| CA2499721A1 (en) | Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists | |
| JP2005533064A5 (https=) | ||
| JP2004532267A5 (https=) |